Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer.

Thomas L, Baratchian M, Sharifi N.

Eur Urol. 2019 Jul 31. pii: S0302-2838(19)30596-2. doi: 10.1016/j.eururo.2019.07.037. [Epub ahead of print] No abstract available.

PMID:
31377027
2.

HSD3B1 Genotypes Conferring Adrenal Restrictive and Adrenal Permissive Phenotypes in Prostate Cancer and Beyond.

Sabharwal N, Sharifi N.

Endocrinology. 2019 Jul 4. pii: en.2019-00366. doi: 10.1210/en.2019-00366. [Epub ahead of print]

PMID:
31271415
3.

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.

Oncogene. 2019 Jun;38(23):4496-4511. doi: 10.1038/s41388-019-0732-7. Epub 2019 Feb 11.

PMID:
30742064
4.

Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging.

Zhu Z, Chung YM, Sergeeva O, Kepe V, Berk M, Li J, Ko HK, Li Z, Petro M, DiFilippo FP, Lee Z, Sharifi N.

J Biol Chem. 2018 Nov 16;293(46):17829-17837. doi: 10.1074/jbc.RA118.004846. Epub 2018 Sep 27.

PMID:
30262668
5.

Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression.

Gao X, Dai C, Huang S, Tang J, Chen G, Li J, Zhu Z, Zhu X, Zhou S, Gao Y, Hou Z, Fang Z, Xu C, Wang J, Wu D, Sharifi N, Li Z.

Clin Cancer Res. 2019 Feb 15;25(4):1291-1301. doi: 10.1158/1078-0432.CCR-18-2392. Epub 2018 Sep 18.

PMID:
30228209
6.

A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.

Blanchet B, Carton E, Alyamani M, Golmard L, Huillard O, Thomas-Scheomann A, Vidal M, Goldwasser F, Sharifi N, Alexandre J.

Pharmacol Res. 2018 Oct;136:56-61. doi: 10.1016/j.phrs.2018.08.016. Epub 2018 Aug 22.

PMID:
30142421
7.

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.

Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N.

J Clin Invest. 2018 Aug 1;128(8):3333-3340. doi: 10.1172/JCI98319. Epub 2018 Jun 25.

8.

AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.

Hettel D, Zhang A, Alyamani M, Berk M, Sharifi N.

Endocrinology. 2018 Aug 1;159(8):2884-2890. doi: 10.1210/en.2018-00283.

9.

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer.

Ko HK, Berk M, Chung YM, Willard B, Bareja R, Rubin M, Sboner A, Sharifi N.

Cell Rep. 2018 Jan 16;22(3):809-819. doi: 10.1016/j.celrep.2017.12.081.

10.

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

Hettel D, Sharifi N.

Nat Rev Urol. 2018 Mar;15(3):191-196. doi: 10.1038/nrurol.2017.201. Epub 2017 Dec 12. Review.

PMID:
29231195
11.

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.

Hearn JWD, Xie W, Nakabayashi M, Almassi N, Reichard CA, Pomerantz M, Kantoff PW, Sharifi N.

JAMA Oncol. 2018 Apr 1;4(4):558-562. doi: 10.1001/jamaoncol.2017.3164.

12.

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.

Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N.

JAMA Oncol. 2018 Apr 1;4(4):554-557. doi: 10.1001/jamaoncol.2017.3159.

13.

Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.

Dai C, Chung YM, Kovac E, Zhu Z, Li J, Magi-Galluzzi C, Stephenson AJ, Klein EA, Sharifi N.

Clin Cancer Res. 2017 Oct 15;23(20):6351-6362. doi: 10.1158/1078-0432.CCR-17-1313. Epub 2017 Jul 21.

14.

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ.

Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3.

PMID:
28655452
15.

Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.

Alyamani M, Li Z, Berk M, Li J, Tang J, Upadhyay S, Auchus RJ, Sharifi N.

Cell Chem Biol. 2017 Jul 20;24(7):825-832.e6. doi: 10.1016/j.chembiol.2017.05.020. Epub 2017 Jun 22.

16.

Androgen Signaling in Prostate Cancer.

Dai C, Heemers H, Sharifi N.

Cold Spring Harb Perspect Med. 2017 Sep 1;7(9). pii: a030452. doi: 10.1101/cshperspect.a030452. Review.

PMID:
28389515
17.

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB.

Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7.

18.

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer.

Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin ME, Garcia JA, Courtney K, Klein EA, Sharifi N.

Elife. 2017 Feb 13;6. pii: e20183. doi: 10.7554/eLife.20183.

19.

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition.

Ornstein MC, Garcia JA, Sharifi N.

Transl Androl Urol. 2016 Aug;5(4):616-9. doi: 10.21037/tau.2016.05.13. No abstract available.

20.

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N.

Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27.

Supplemental Content

Loading ...
Support Center